All articles by Shalini Nair

Shalini Nair

NextCure and LegoChem Biosciences sign agreement to develop antibody drug conjugates

The two firms will share the costs equally in developing the molecules, as well as profits from the marketed products.

Philippines approves Sputnik V Covid-19 vaccine for emergency use

The Food and Drug Administration of the Philippines has given approval to Sputnik V Covid-19 vaccine for emergency use, as the country struggles with spike in infections.

Tonix reports positive Covid-19 vaccine results in TNX-1800-dosed primates

Tonix Pharmaceuticals has reported preliminary positive results after vaccinating monkeys with TNX-1800, a live modified horsepox virus vaccine for percutaneous administration designed to express the Spike protein of SARS-CoV-2 virus and to elicit a predominant T cell response.

Ampio reveals preliminary positive results on inhaled Ampion in Covid-19 respiratory distress

Ampio Pharmaceuticals has revealed preliminary positive results of its AP-014 Phase I clinical trial that involves using of inhaled Ampion in treating respiratory distress in patients due to Covid-19.

Altimmune Covid-19 vaccine candidate prevents SARS-CoV-2 disease in studies

US-based Altimmune has reported that additional preclinical data on its single dose intranasal Covid-19 vaccine candidate, AdCOVID, showed 100% protection against lethal challenge from the SARS-CoV-2 virus, and reduction in viral replication.

WHO issues EUL for J&J’s single-shot Covid-19 vaccine

The World Health Organization (WHO) has issued Emergency Use Listing (EUL) for the single-dose Covid-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) for individuals aged 18 years and above.

Panel finds efficacy for Regeneron’s REGEN-COV in Phase III Covid-19 trial

Regeneron Pharmaceuticals has announced that Independent Data Monitoring Committee (IDMC) found its REGEN-COV antibody cocktail to have clear clinical efficacy in cutting down the rates of hospitalisation and deaths in patients in a Phase III Covid-19 outpatient trial.

CDRI gets approval for Phase III trial of Umifenovir to treat Covid-19

Central Drug Research Institute (CDRI), a constituent lab of India-based Council of Scientific and Industrial Research (CSIR), has secured approval for carrying out Phase III trial for the use of Umifenovir in the treatment of Covid-19.